The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032

Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects

H. Y. Ahn, M. Kim, Y. T. Ahn, J. H. Sim, I. D. Choi, S. H. Lee, Jong Ho Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and aims: This study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus (. L. curvatus) HY7601 and Lactobacillus plantarum (. L. plantarum) KY1032 on the fasting plasma metabolome. Methods and results: A randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2g of powder containing 5×109colony-forming units (cfu) of L. curvatus HY7601 and 5×109cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20% reduction (p=0.001) in serum TGs and 25% increases (p=0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (Δ) in TG were negatively correlated with Δ apoA-V, which was positively correlated with Δ FFA. In addition, Δ FFA was strongly and positively correlated with Δ lysoPCs in the probiotic group but not the placebo group. Conclusions: The triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs (. NCT02215694; http://www.clinicaltrials.gov).Clinical trials: NCT02215694; http://www.clinicaltrials.gov.

Original languageEnglish
Pages (from-to)724-733
Number of pages10
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume25
Issue number8
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Lactobacillus plantarum
Lysophosphatidylcholines
Probiotics
Lactobacillus
Fasting
Triglycerides
Placebos
Metabolome
Amides
Hypertriglyceridemia
Choline
Powders
Fatty Acids
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

@article{03c295bbd8ec49949e9f845a94137633,
title = "The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects",
abstract = "Background and aims: This study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus (. L. curvatus) HY7601 and Lactobacillus plantarum (. L. plantarum) KY1032 on the fasting plasma metabolome. Methods and results: A randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2g of powder containing 5×109colony-forming units (cfu) of L. curvatus HY7601 and 5×109cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20{\%} reduction (p=0.001) in serum TGs and 25{\%} increases (p=0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (Δ) in TG were negatively correlated with Δ apoA-V, which was positively correlated with Δ FFA. In addition, Δ FFA was strongly and positively correlated with Δ lysoPCs in the probiotic group but not the placebo group. Conclusions: The triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs (. NCT02215694; http://www.clinicaltrials.gov).Clinical trials: NCT02215694; http://www.clinicaltrials.gov.",
author = "Ahn, {H. Y.} and M. Kim and Ahn, {Y. T.} and Sim, {J. H.} and Choi, {I. D.} and Lee, {S. H.} and Lee, {Jong Ho}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.numecd.2015.05.002",
language = "English",
volume = "25",
pages = "724--733",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032

T2 - Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects

AU - Ahn, H. Y.

AU - Kim, M.

AU - Ahn, Y. T.

AU - Sim, J. H.

AU - Choi, I. D.

AU - Lee, S. H.

AU - Lee, Jong Ho

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background and aims: This study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus (. L. curvatus) HY7601 and Lactobacillus plantarum (. L. plantarum) KY1032 on the fasting plasma metabolome. Methods and results: A randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2g of powder containing 5×109colony-forming units (cfu) of L. curvatus HY7601 and 5×109cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20% reduction (p=0.001) in serum TGs and 25% increases (p=0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (Δ) in TG were negatively correlated with Δ apoA-V, which was positively correlated with Δ FFA. In addition, Δ FFA was strongly and positively correlated with Δ lysoPCs in the probiotic group but not the placebo group. Conclusions: The triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs (. NCT02215694; http://www.clinicaltrials.gov).Clinical trials: NCT02215694; http://www.clinicaltrials.gov.

AB - Background and aims: This study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus (. L. curvatus) HY7601 and Lactobacillus plantarum (. L. plantarum) KY1032 on the fasting plasma metabolome. Methods and results: A randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2g of powder containing 5×109colony-forming units (cfu) of L. curvatus HY7601 and 5×109cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20% reduction (p=0.001) in serum TGs and 25% increases (p=0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (Δ) in TG were negatively correlated with Δ apoA-V, which was positively correlated with Δ FFA. In addition, Δ FFA was strongly and positively correlated with Δ lysoPCs in the probiotic group but not the placebo group. Conclusions: The triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs (. NCT02215694; http://www.clinicaltrials.gov).Clinical trials: NCT02215694; http://www.clinicaltrials.gov.

UR - http://www.scopus.com/inward/record.url?scp=84937513707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937513707&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2015.05.002

DO - 10.1016/j.numecd.2015.05.002

M3 - Article

VL - 25

SP - 724

EP - 733

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 8

ER -